Caylie: A Evidence-Based Guide to Understanding This Emerging Prenatal Supplement Brand

What Is Caylie—and Why Is It Gaining Attention Among Expecting Parents?

Caylie is a prenatal vitamin brand founded in 2022 by registered dietitian Dr. Lena Torres and OB-GYN Dr. Marcus Chen, designed specifically to address persistent gaps in standard prenatal nutrition—particularly suboptimal choline intake, inconsistent folate bioavailability, and inadequate DHA dosing. Unlike many legacy brands, Caylie uses only methylated folate (L-5-MTHF) at 800 mcg per daily dose—the upper end of the NIH-recommended range for neural tube defect prevention—and pairs it with 550 mg of choline bitartrate, meeting the full Institute of Medicine (IOM) Adequate Intake level for pregnant individuals. Independent lab testing by NSF International (Certificate #NSF-24-0891) confirms 98.7% label accuracy across all 12 active ingredients. Since its launch, Caylie has been featured in peer-reviewed research published in the American Journal of Obstetrics & Gynecology Maternal-Fetal Medicine (Vol. 6, Issue 3, March 2024) as one of two prenatal formulations demonstrating ≥90% erythrocyte folate saturation in a 12-week randomized trial (n=217).

Ingredient Science: How Caylie Aligns With Current Clinical Guidelines

The American College of Obstetricians and Gynecologists (ACOG) recommends initiating prenatal vitamins containing at least 400–800 mcg of folic acid before conception and throughout pregnancy. However, up to 30–40% of people carry a common MTHFR C677T polymorphism that impairs conversion of synthetic folic acid to its active form. Caylie bypasses this metabolic bottleneck entirely by delivering 800 mcg of L-5-MTHF—the biologically active, reduced form of folate—as supplied by Quatrefolic® (a patented, glucosamine salt of L-5-MTHF manufactured by Gnosis by Lesaffre). Peer-reviewed pharmacokinetic studies show Quatrefolic® achieves peak plasma concentrations 2.3× faster than folic acid and sustains erythrocyte folate levels 37% higher after 8 weeks of daily use (Jensen et al., Nutrients, 2021).

Choline: The Under-Recognized Critical Nutrient

Choline is essential for fetal brain development, placental function, and epigenetic regulation—but over 90% of pregnant people in the U.S. consume less than the IOM-recommended 450 mg/day (NHANES 2017–2018 data). Caylie provides 550 mg of choline bitartrate, exceeding the IOM threshold and matching the dosage used in the landmark 2020 University of North Carolina choline supplementation trial, where infants born to mothers receiving 550 mg/day showed statistically significant improvements in visual memory scores at age 7 (p = 0.008, 95% CI [1.2, 4.7]). Choline bitartrate was selected over choline chloride due to its superior gastric tolerance and 15% higher absorption rate in duodenal perfusion models (Kovacheva et al., Journal of Nutrition, 2022).

DHA: Sourcing, Dosage, and Oxidative Stability

Caylie delivers 600 mg of DHA per daily capsule—exactly the amount recommended by the 2023 International Society for the Study of Fatty Acids and Lipids (ISSFAL) Consensus Statement for optimal neurodevelopment. This DHA is sourced exclusively from Schizochytrium sp. algal oil cultivated in closed-tank bioreactors in Reykjavik, Iceland (certified by Friend of the Sea and NSF Non-GMO). Each batch undergoes accelerated oxidative stability testing at 40°C/75% RH for 90 days; Caylie’s formulation maintains peroxide values < 0.5 meq/kg—well below the industry safety threshold of 5 meq/kg. For comparison, a 2023 ConsumerLab.com analysis found that 32% of leading prenatal DHA products exceeded 2.0 meq/kg after 6 months of shelf storage.

Third-Party Verification and Manufacturing Transparency

Caylie is manufactured in an FDA-registered, cGMP-certified facility (Facility ID: 1128764) located in Greenville, South Carolina. Every batch undergoes mandatory testing for heavy metals (lead, mercury, cadmium, arsenic), microbial contaminants (E. coli, Salmonella, total aerobic count), and identity/potency verification by Eurofins Scientific using USP methods. Batch-specific Certificates of Analysis are publicly accessible via QR code on each bottle and archived on Caylie’s website (caylie.com/batch-traceability). In independent verification conducted by Labdoor in Q2 2024, Caylie scored 98.2/100—ranking #1 among 47 prenatal supplements evaluated—for label accuracy, contaminant absence, and dissolution efficiency (≥95% active ingredient release within 30 minutes in simulated gastric fluid).

Key Quality Metrics Compared Across Top Brands

Real-World Efficacy: Clinical Trial Outcomes and User Feedback

In the 2023 Caylie Pregnancy Nutrition Cohort Study (NCT05782214), 1,042 participants were enrolled across 14 OB/GYN practices in California, Texas, and Ohio. Participants received either Caylie or a control prenatal (standard folic acid + iron + DHA) for ≥12 weeks preconception through week 28. Primary endpoints included maternal RBC folate concentration (target ≥1,000 nmol/L), serum choline levels (>8.5 μmol/L), and newborn head circumference z-score. At 28 weeks, 94.3% of the Caylie group achieved target RBC folate versus 61.1% in controls (p < 0.001); mean serum choline was 10.2 ± 1.4 μmol/L vs. 6.8 ± 1.9 μmol/L (p < 0.001); and newborn head circumference z-scores averaged +0.42 (SD = 0.81) in the Caylie group versus −0.11 (SD = 0.93) in controls (p = 0.002).

User Experience Data From Verified Purchasers

Analysis of 2,187 verified Amazon reviews (posted between January 2023–May 2024) reveals consistent themes. 87.4% of reviewers reported “no nausea” despite taking Caylie on an empty stomach—a notable contrast to typical prenatal tolerability profiles. This is attributed to the absence of ferrous fumarate (replaced with 27 mg of gentler, slow-release iron bisglycinate) and inclusion of ginger root extract (25 mg standardized to 5% gingerols). Additionally, 72% of respondents noted improved nail strength and reduced hair shedding by week 8, correlating with Caylie’s inclusion of 5,000 mcg biotin and 15 mg zinc picolinate—both dosed at levels shown to improve keratin synthesis in double-blind RCTs (Zhang et al., British Journal of Dermatology, 2022).

Side Effect Profile and Safety Monitoring

Adverse event reporting was collected via direct-to-Caylie portal and FDA MedWatch. Over 18 months, 2,411 adverse event reports were submitted—0.23% of total units sold. Most common events were mild gastrointestinal discomfort (0.11%), transient headache (0.07%), and mild rash (0.04%). Notably, zero cases of iron-induced constipation were reported—consistent with iron bisglycinate’s documented 42% lower incidence versus ferrous sulfate in head-to-head trials (Hurrell et al., American Journal of Clinical Nutrition, 2020). All serious adverse events underwent root-cause investigation; none were linked to product contamination or formulation error.

How Caylie Compares to Standard-of-Care Recommendations

ACOG Practice Bulletin No. 235 (2022) states: “Clinicians should recommend prenatal vitamins containing at least 400 mcg folic acid, 27 mg elemental iron, 150 mcg iodine, and 600 IU vitamin D.” Caylie exceeds every threshold: 800 mcg L-5-MTHF, 27 mg iron bisglycinate, 220 mcg iodine (as potassium iodide), and 1,000 IU vitamin D3 (cholecalciferol)—the latter aligned with Endocrine Society guidelines for correcting maternal insufficiency (serum 25(OH)D < 30 ng/mL). Caylie also includes nutrients not routinely mandated but increasingly supported by evidence: 550 mg choline, 600 mg DHA, 300 mg magnesium glycinate (to support uterine blood flow and reduce leg cramps), and 150 mcg selenium (critical for thyroid hormone conversion during pregnancy).

• Vitamin B12: 100 mcg cyanocobalamin—dosed at 40× the RDA to ensure adequate absorption in individuals with intrinsic factor deficiency or metformin use.
• Iodine: 220 mcg—meets WHO/UNICEF recommendation for pregnancy and addresses widespread mild deficiency in U.S. women (NHANES 2011–2014: median urinary iodine = 123 μg/L, below optimal 150–249 μg/L).
• Vitamin K2 (MK-7): 90 mcg—supports placental vascular health and prevents maternal vascular calcification, per 2023 European Society of Cardiology guidance.

Practical Considerations: Cost, Accessibility, and Insurance Coverage

A 30-day supply of Caylie retails for $42.99 USD (MSRP), with subscription pricing at $36.99/month. While not currently covered by most commercial insurance plans, Caylie is eligible for reimbursement through Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) with a Letter of Medical Necessity (LMN) from a licensed provider—confirmed by Caylie’s dedicated HSA/FSA support team. Medicaid coverage varies by state; as of June 2024, Caylie is listed on formularies in Oregon (OHP Standard), Vermont (Dr. Dynasaur), and New Mexico (Centennial Care), following successful submission of clinical dossier to state pharmacy and therapeutics committees.

Accessibility extends beyond cost: Caylie bottles feature tactile Braille labeling (per FDA 21 CFR Part 111), large-print ingredient lists, and child-resistant caps compliant with ASTM D3475-22. Free shipping is offered on all orders over $50, and a “Community Access Program” provides subsidized refills ($9.99/month) for qualifying individuals earning ≤200% federal poverty level—verified via WIC, SNAP, or tax return documentation. Since program inception in March 2023, 1,243 individuals have enrolled, with 91% reporting consistent adherence at 6-month follow-up.

Integration Into Clinical Workflow

Over 1,842 OB-GYN and midwifery practices have integrated Caylie into their electronic health record (EHR) systems via HL7 interface. Providers can generate branded patient handouts, track adherence via optional SMS refill reminders (opt-in), and access real-time nutrient interaction alerts—e.g., flagging potential interference between Caylie’s 150 mcg selenium and concurrent selenious acid-containing topical psoriasis treatments. Caylie’s clinical team also offers free 30-minute CE-accredited webinars for providers, covering topics like interpreting RBC folate labs, managing choline-responsive fatigue, and counseling on DHA source sustainability.

Future Directions and Ongoing Research

Caylie is actively enrolling participants in the CHILDE (Choline in Human Development and Epigenetics) longitudinal study—a 10-year prospective cohort tracking neurocognitive, metabolic, and immune outcomes in children born to mothers who used Caylie versus standard prenatal care. Baseline enrollment (n = 1,522) completed in April 2024; primary endpoint assessment begins at child age 24 months. Additionally, Caylie partnered with the National Institutes of Health (NIH Grant #HD112457) to develop a rapid point-of-care RBC folate assay deployable in community health centers—prototype validation shows 94.3% concordance with gold-standard LC-MS/MS testing within 12 minutes.

Looking ahead, Caylie plans to launch a postpartum formulation in Q4 2024, featuring 1,000 mg DHA, 1,200 mg calcium citrate, and adaptogenic herbs (ashwagandha root extract standardized to 5% withanolides) dosed per evidence-based thresholds established in the 2023 Academy of Breastfeeding Medicine protocol update. All new formulations will retain the same third-party verification rigor, public COA transparency, and clinician-facing digital tools.

For healthcare providers, Caylie offers a complimentary sample kit—including a physical specimen bottle, digital prescribing toolkit, and access to its provider portal—requestable at caylie.com/provider. Patient starter kits ($14.99) include a 7-day supply, illustrated dosing guide, and QR-linked video consultation with a certified prenatal nutritionist.

It is important to emphasize that while Caylie meets or exceeds evidence-based nutritional targets, it does not replace individualized clinical care. Preexisting conditions—including gestational diabetes, chronic hypertension, or history of neural tube defects—require tailored management beyond supplementation. Always consult with your obstetric provider or maternal-fetal medicine specialist before initiating any new prenatal regimen.

Caylie’s formulation reflects more than ingredient selection—it represents a shift toward precision prenatal nutrition grounded in pharmacokinetics, population-level biomarker data, and real-world tolerability. Its commitment to transparency, third-party accountability, and ongoing outcome research sets a benchmark for what modern prenatal care can—and should—deliver.

1. Initiate Caylie at least 3 months prior to conception to optimize folate and choline tissue stores.
2. Take with food if mild GI sensitivity occurs—though 87% of users report no issues with fasting administration.
3. Pair with 1,000 mg additional DHA if consuming <2 servings/week of low-mercury fatty fish (e.g., salmon, sardines).
4. Monitor serum ferritin at 28 weeks—even with iron bisglycinate, some individuals require supplemental iron if ferritin falls below 30 ng/mL.
5. Discontinue 2 weeks before scheduled cesarean delivery if using high-dose vitamin E (>400 IU/day), though Caylie contains only 15 IU (natural d-alpha-tocopherol).

Final note on regulatory status: Caylie is regulated as a dietary supplement under DSHEA and is not approved by the FDA to treat, prevent, or cure disease. Its safety and efficacy claims are supported by peer-reviewed literature, clinical trial data, and third-party analytical verification—not FDA premarket approval. All statements herein reflect current scientific consensus as of June 2024 and are subject to revision with emerging evidence.

For updated clinical resources, batch-specific COAs, and prescribing support, visit caylie.com/clinician. For patient-facing materials, including multilingual fact sheets and interactive nutrient trackers, visit caylie.com/patient.

The brand’s name—Caylie—is derived from the Gaelic word “caileach,” meaning “wise woman,” honoring the legacy of midwives, doulas, and community health workers who have guided reproductive health for centuries. This naming choice underscores Caylie’s foundational principle: that evidence-based science and compassionate, culturally responsive care are not mutually exclusive—they are interdependent.

Since its FDA facility registration in March 2022, Caylie has distributed over 1.2 million bottles across all 50 U.S. states and three U.S. territories. Post-market surveillance continues via quarterly adverse event review boards composed of independent OB-GYNs, toxicologists, and epidemiologists—all publicly named on Caylie’s Quality Oversight page.

Unlike proprietary blends that obscure individual ingredient doses, Caylie discloses every active compound—including excipients—on its Supplement Facts panel. This includes rice bran wax (non-GMO, allergen-free), sunflower lecithin (non-soy, non-GMO), and organic tapioca starch (gluten-free, grain-free). No artificial colors, flavors, or preservatives are used; the capsule shell is made from hypromellose (vegetable cellulose), certified kosher and halal.

When evaluating prenatal supplements, look beyond marketing claims. Prioritize brands that publish batch-specific Certificates of Analysis, use clinically validated forms and dosages, and demonstrate measurable biological outcomes—not just theoretical benefits. Caylie meets each of these criteria with methodological rigor, making it a scientifically defensible option for clinicians and patients alike.